Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations

por Gauri A. Patwardhan, Michal Marczyk, Vikram B. Wali, David F. Stern, Lajos Pusztai, Christos Hatzis
Publicado 2021

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

por Jamunarani Veeraraghavan, Carolina Gutierrez, Vidyalakshmi Sethunath, Sepideh Mehravaran, Mario Giuliano, Martin J. Shea, Tamika Mitchell, Tao Wang, Sarmistha Nanda, Resel Pereira, Robert Davis, Kristina Goutsouliak, Lanfang Qin, Carmine De Angelis, Irmina Diala, Alshad S. Lalani, Chandandeep Nagi, Susan G. Hilsenbeck, Mothaffar F. Rimawi, C. Kent Osborne, Rachel Schiff
Publicado 2021

Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis

por Sandra Parenti, Sebastiano Rontauroli, Chiara Carretta, Selene Mallia, Elena Genovese, Chiara Chiereghin, Clelia Peano, Lara Tavernari, Elisa Bianchi, Sebastian Fantini, Stefano Sartini, Oriana Romano, Silvio Bicciato, Enrico Tagliafico, Matteo Della Porta, Rossella Manfredini
Publicado 2021

The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia

por Kinjal Shah, Mehreen Ahmed, Julhash U. Kazi
Publicado 2021

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

por Leticia De Mattos-Arruda, Javier Cortes, Juan Blanco-Heredia, Daniel G. Tiezzi, Guillermo Villacampa, Samuel Gonçalves-Ribeiro, Laia Paré, Carla Anjos Souza, Vanesa Ortega, Stephen-John Sammut, Pol Cusco, Roberta Fasani, Suet-Feung Chin, Jose Perez-Garcia, Rodrigo Dienstmann, Paolo Nuciforo, Patricia Villagrasa, Isabel T. Rubio, Aleix Prat, Carlos Caldas
Publicado 2021

Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis

por Sixten Harborg, Robert Zachariae, Julia Olsen, Maja Johannsen, Deirdre Cronin-Fenton, Henrik Bøggild, Signe Borgquist
Publicado 2021

Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions

por Binghao Li, Hao Qu, Jing Zhang, Weibo Pan, Meng Liu, Xiaobo Yan, Xin Huang, Xuexin He, Dong Lin, Sisi Liu, Ruting Guan, Yong Wu, Qiuxiang Ou, Hua Bao, Youbin Xu, Xue Wu, Yang Shao, Nong Lin
Publicado 2021

Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target

por Nathan D. Seligson, Richard D. Maradiaga, Colin M. Stets, Howard M. Katzenstein, Sherri Z. Millis, Alan Rogers, John L. Hays, James L. Chen
Publicado 2021

Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment

por Naixue Yang, Fansen Ji, Liqing Cheng, Jingzhe Lu, Xiaofeng Sun, Xin Lin, Xun Lan
Publicado 2021

First-line treatment of advanced ALK-positive non-small-cell lung cancer

por Gandhi S, Chen H, Zhao Y, Dy GK
Publicado 2015

Update on biomarkers for the detection of lung cancer

por Jantus-Lewintre E, Usó M, Sanmartín E, Camps C
Publicado 2012

Challenges in the development of future treatments for breast cancer stem cells

por Shyam A Patel, Anicia Ndabahaliye, Philip K Lim, et al
Publicado 2010

Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer

por Zienolddiny S, Skaug V
Publicado 2011

Retraction

por Singhai R
Publicado 2012

Preserving fertility in patients undergoing treatment for breast cancer: current perspectives

por Moffat R, Güth U
Publicado 2014

Effectiveness of maintenance treatments for nonsmall cell lung cancer

por Eadens MJ, Robinson SI, Price KA
Publicado 2011

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer

por Abdel Kader Y, Spielmann M, El-Nahas T, Sakr A, Metwally H
Publicado 2013

A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer

por Yokoi T, Tamaki T, Shimizu T, Nomura S
Publicado 2012

Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective

por Machado M, Einarson TR
Publicado 2012

Optimal delivery of male breast cancer follow-up care: improving outcomes

por Ferzoco RM, Ruddy KJ
Publicado 2015